Novartis and Orionis strike second molecular glue deal for $40M upfront
Novartis is doubling down on its partnership with Orionis Biosciences in a deal worth $40 million upfront and up to $1.4 billion spread across milestones. The B...
Novartis is doubling down on its partnership with Orionis Biosciences in a deal worth $40 million upfront and up to $1.4 billion spread across milestones. The Boston and Belgian biotech will ...